Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/bcp.12836 http://scihub22266oqcxt.onion/10.1111/bcp.12836 C4799939!4799939!26580706     free     free     free Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 261.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 261.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26580706.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Br+J+Clin+Pharmacol 2016 ; 81 (4): 724-34 Nephropedia Template TP {{tp|p=26580706|t=2016. Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co?medication interactions |pdf=|usr=}}{{26580706}} gab.com Text Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co medication interactions JO: Br J Clin Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=26580706 #FOAvip Aim: The aim of the present study was to analyse concomitant drug use and its association with outcome in patients (N = 17 701) receiving rivaroxaban or standard of care (SOC) for the prevention of venous thromboembolism after major orthopaedic surgery in the non?interventional, phase IV XAMOS (Xarelto® in the prophylaxis of post?surgical venous thromboembolism after elective major orthopaedic surgery of hip or knee) study. Methods: Concomitant drug use was at the discretion of the treating physician. Prespecified co?medications of interest were cytochrome P450 (CYP) 3A4/P?glycoprotein inhibitors/inducers, platelet aggregation inhibitors (PAIs) and nonsteroidal anti?inflammatory drugs (NSAIDs). Crude event incidences were compared between rivaroxaban and SOC groups. Results: CYP3A4/P?glycoprotein inhibitor/inducer use was infrequent, in contrast to PAI (~7%) and NSAID (~52%) use. Rivaroxaban was associated with a lower incidence of overall symptomatic thromboembolic events compared with SOC, regardless of co?medication use. In both treatment groups, PAI users, with higher age and prevalence of cardiovascular co?morbidities, had similar higher (>7?fold) incidences of symptomatic arterial but not venous thromboembolic events compared with non?users. NSAID use had no influence on thromboembolic events. However, odds ratios (ORs) for major bleeding events (European Medicines Agency definition) were higher in NSAID users compared with non?users in rivaroxaban [OR = 1.50; 95% confidence interval (CI) 1.06, 2.13] and SOC (OR = 1.70; CI 1.16, 2.49) groups. In PAI users, ORs for major bleeding events were no different from those of non?users in both the rivaroxaban (OR = 1.49; CI 0.84, 2.65) and SOC (OR = 1.46; CI 0.82, 2.62) groups. Conclusions: Use of NSAIDs in XAMOS was frequent and associated with a higher frequency of bleeding events in patients receiving rivaroxaban or SOC, although the benefit?risk profile of rivaroxaban compared with SOC was maintained. Twit Text FOAVip Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co medication interactions ????Br J Clin Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=26580706 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26580706 #FOAvip English Wikipedia <ref>{{Cite pmid|26580706}}</ref> Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co?medication interactions #MMPMID26580706 Kreutz R; Haas S; Holberg G; Lassen MR; Mantovani LG; Schmidt A; Turpie AGG Br J Clin Pharmacol 2016[Apr]; 81 (4): 724-34 PMID26580706show ga Aim: The aim of the present study was to analyse concomitant drug use and its association with outcome in patients (N = 17 701) receiving rivaroxaban or standard of care (SOC) for the prevention of venous thromboembolism after major orthopaedic surgery in the non?interventional, phase IV XAMOS (Xarelto® in the prophylaxis of post?surgical venous thromboembolism after elective major orthopaedic surgery of hip or knee) study. Methods: Concomitant drug use was at the discretion of the treating physician. Prespecified co?medications of interest were cytochrome P450 (CYP) 3A4/P?glycoprotein inhibitors/inducers, platelet aggregation inhibitors (PAIs) and nonsteroidal anti?inflammatory drugs (NSAIDs). Crude event incidences were compared between rivaroxaban and SOC groups. Results: CYP3A4/P?glycoprotein inhibitor/inducer use was infrequent, in contrast to PAI (~7%) and NSAID (~52%) use. Rivaroxaban was associated with a lower incidence of overall symptomatic thromboembolic events compared with SOC, regardless of co?medication use. In both treatment groups, PAI users, with higher age and prevalence of cardiovascular co?morbidities, had similar higher (>7?fold) incidences of symptomatic arterial but not venous thromboembolic events compared with non?users. NSAID use had no influence on thromboembolic events. However, odds ratios (ORs) for major bleeding events (European Medicines Agency definition) were higher in NSAID users compared with non?users in rivaroxaban [OR = 1.50; 95% confidence interval (CI) 1.06, 2.13] and SOC (OR = 1.70; CI 1.16, 2.49) groups. In PAI users, ORs for major bleeding events were no different from those of non?users in both the rivaroxaban (OR = 1.49; CI 0.84, 2.65) and SOC (OR = 1.46; CI 0.82, 2.62) groups. Conclusions: Use of NSAIDs in XAMOS was frequent and associated with a higher frequency of bleeding events in patients receiving rivaroxaban or SOC, although the benefit?risk profile of rivaroxaban compared with SOC was maintained. äRivaroxaban compared with standard thromboprophylaxis after major orth(epmc).pdf DeepDyve Pubget Overpricing